Anti-CD38 Antibodies for Checkpoint Resistance in Blood Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies targeting CD38, such as PD-1/PD-L1 blockade, face significant resistance in treating hematopoietic malignancies, necessitating the development of antibodies that can effectively inhibit CD38 to enhance antitumor immune responses.
Innovation Solution
Development of antibodies that specifically bind to CD38 with high affinity and inhibit its activity, potentially combined with other immune checkpoint inhibitors like PD-L1, to overcome therapeutic resistance in hematopoietic malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1/PD-L1 blockade therapy is used, then immune checkpoint inhibition is achieved, but therapeutic resistance occurs due to CD38 upregulation
Solution Approach 1:
The patent segments the immune checkpoint inhibition strategy into two distinct targets: PD-1/PD-L1 pathway and CD38 pathway. By developing separate antibody agents for each target that can be administered individually or in combination, the therapy addresses multiple resistance mechanisms simultaneously, thereby improving overall therapeutic reliability while mitigating the harmful effect of CD38-mediated resistance.
Solution Approach 2:
The patent employs a composite therapeutic approach by combining anti-PD-1/PD-L1 antibodies with anti-CD38 antibodies. This composite strategy targets two different immune checkpoint pathways concurrently, creating a synergistic effect that overcomes the therapeutic resistance caused by CD38 upregulation while maintaining the benefits of PD-1/PD-L1 blockade.
2Reliability
If CD38 is targeted for therapy, then antitumor immune response is enhanced, but antibody development complexity increases
Solution Approach 1:
The patent develops anti-CD38 antibodies with multiple functional capabilities: they block CD38 enzymatic activity, prevent ligand binding, and can be administered alone or in combination with other checkpoint inhibitors. This multi-functionality allows a single antibody development effort to address multiple therapeutic needs, enhancing antitumor immune response while managing development complexity through versatile agent design.
Data Source
AI summary
The present disclosure provides antibodies that specifically bind to CD38. The antibodies find use in a variety of treatment, diagnostic, and monitoring applications, which are also described. The present disclosure provides antibodies that specifically bind to, and in some embodiments, inhibit CD38. A subject antibody specifically binds CD38 from humans and other mammals, e.g., monkey and mouse.